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INTRODUCTION
Myosin heavy chain isoforms are traditionally known to be major
structural components of the heart muscle contractile apparatus.
The myocardia of the atrial and ventricular chambers differ in their
contractile and electrophysiological properties, which are partly
determined by the expression of certain genes. In humans and
chick, the ‘cardiac’ myosin heavy chain genes, alpha MYH (MYH
or atrial MYH) and beta MYH (MYH or ventricular MYH), are
located on separate chromosomes, whereas the ‘skeletal’ MYH
genes are clustered together on the same chromosome. During
development and in the adult, MYH is predominately expressed
in the atrial chamber and MYH in the ventricular chamber in both
humans and chicks (Oana et al., 1998; Reiser et al., 2001; Somi et
al., 2006; Wessels et al., 2000; Wessels et al., 1991). Of the skeletal
genes, four are expressed in the heart in the chicken. Neonatal fast,
slow skeletal and slow tonic MYH are predominately expressed in
the heart conductive cells (Gonzalez-Sanchez and Bader, 1985;
Machida et al., 2000; Machida et al., 2002). Although embryonic
MYH (eMYH) has been shown to be expressed in the myotome,
skeletal muscle and chick heart late in development (from day 12)
(Gulick et al., 1987; Lagrutta et al., 1989; Lyons et al., 1990;
Merrifield et al., 1989; Sacks et al., 2003), expression during early
cardiogenesis has not been determined. To our knowledge, none of
the skeletal MYH genes is known to be expressed in the human
heart.
Looping of the primitive heart tube is initiated from Hamburger
and Hamilton stage (HH) 10 (during day 2) in the chick
(Hamburger and Hamilton, 1951; Sissman, 1970). This tube is
subsequently divided into chambers by the formation of septa, a
process initiated in the primitive single atrium from the
dorsocranial wall at ~HH14 (Hendrix and Morse, 1977; Morse,
1978; Quiring, 1933). This septum primum extends into the
chamber and ultimately fuses with endocardial cushions, dividing
the heart into left and right atrial chambers. In humans, atrial septal
defects (ASDs) occur in approximately 1 in 1500 live births. The
molecular genetics of ASDs are being elucidated with mutations
found in a number of genes, including the transcription factors
Nkx2.5, Tbx5 and Gata4, and the structural proteins MYH6, MYH7
and alpha cardiac actin (Wessels and Willems, 2010). Although
these mutations have provided important insights into cardiac
morphogenesis and ASD formation, in many families and
individuals the causative gene is still unknown.
Cardiomyopathies are contractile diseases of the heart that are
associated with heart enlargement and dysfunction. The two most
common types are hypertrophic and dilated cardiomyopathy (CM).
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SUMMARY
The expression and function of embryonic myosin heavy chain (eMYH) has not been investigated within the early developing
heart. This is despite the knowledge that other structural proteins, such as alpha and beta myosin heavy chains and cardiac alpha
actin, play crucial roles in atrial septal development and cardiac function. Most cases of atrial septal defects and cardiomyopathy
are not associated with a known causative gene, suggesting that further analysis into candidate genes is required. Expression
studies localised eMYH in the developing chick heart. eMYH knockdown was achieved using morpholinos in a temporal manner
and functional studies were carried out using electrical and calcium signalling methodologies. Knockdown in the early embryo
led to abnormal atrial septal development and heart enlargement. Intriguingly, action potentials of the eMYH knockdown hearts
were abnormal in comparison with the alpha and beta myosin heavy chain knockdowns and controls. Although
myofibrillogenesis appeared normal, in knockdown hearts the tissue integrity was affected owing to apparent focal points of
myocyte loss and an increase in cell death. An expression profile of human skeletal myosin heavy chain genes suggests that
human myosin heavy chain 3 is the functional homologue of the chick eMYH gene. These data provide compelling evidence that
eMYH plays a crucial role in important processes in the early developing heart and, hence, is a candidate causative gene for atrial
septal defects and cardiomyopathy.
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Hypertrophic CM (HCM) is defined as the unexplained presence
of a notable thickening of the ventricular wall and dilated CM
(DCM) is defined by ventricular dilatation and decreased
contractile function (Maron et al., 2006). Mutations in a range of
human sarcomeric genes have been associated with both HCM and
DCM, including MYH6 (human homologue of MYH) and MYH7
(human homologue of MYH) (Carniel et al., 2005; Niimura et al.,
2002; Walsh et al., 2010). It is also of note that children can be
afflicted with cardiomyopathy (Towbin et al., 2006). Interestingly,
mutations in the structural proteins MYH6, MYH7 and alpha
cardiac actin have been associated with cardiomyopathy and ASDs
in humans (Budde et al., 2007; Carniel et al., 2005; Ching et al.,
2005; Matsson et al., 2008; Mogensen et al., 2004; Monserrat et al.,
2007; Olson et al., 1998).
Although eMYH was isolated and sequenced in 1987 (Molina et
al., 1987), little has been done to describe its role during heart
development. We describe here that eMYH is present in the early
developing heart and that upon knockdown during early
cardiogenesis, the atrial septa developed abnormally. In addition,
the hearts had ventricular DCM and disrupted trabeculae
development, and most ventricular cardiomyocytes were either
electrically inactive or abnormalities in electrical activities were
observed. Although the sarcomeres appeared normal, tissue
integrity was compromised and apoptosis levels were increased.
These data suggest that the structural protein eMYH is a candidate
gene for ASDs and DCM, and is crucial for normal contractile
function.
MATERIALS AND METHODS
Morpholino design
Two morpholinos were designed against eMYH (accession number J02714)
(Molina et al., 1987): 5-TCAGCATCTGTAGCCATCGTCGCT-3 (first
experimental designed to translational start site) and 5-
TTATTGGGAGTAATGCAGCAAGTAT-3 (second experimental designed
upstream of start site). A 5 base pair (bp) mismatch (indicated in lower case)
negative control morpholino (5-TCAcCATCTcTAcCCATCcTCcCT-3) and
a GeneTools standard control (SC) morpholino (to mutated human beta-
globin gene; 5-CCTCTTACCTCAGTTACAATTTATA-3) were used. An
MYH morpholino was used as described previously (Rutland et al., 2009).
A translational start site morpholino for MYH (5-
CCGTCATGTCCATCATCTTGGCAAG-3) was designed. Morpholinos
were fluorescein or lissamine tagged (GeneTools LLC, USA) and underwent
strict sequence similarity testing to ensure gene specificity.
eMYH knockdown
Knockdown was performed as previously described (Rutland et al., 2009)
using fertile chicken eggs (Gallus gallus; Henry Stewart, UK) at HH12,
HH14 or HH16 (Hamburger and Hamilton, 1951), equivalent to 50, 54 and
57 hours incubation, respectively. Studies were performed within national
(UK Home Office) and institutional ethical regulations. When determining
the optimal concentration of eMYH morpholino, 125 M, 250 M or 500
M were achieved by resuspension in equal amounts of 30% F127 pluronic
gel (BASF Corporation, Germany) and HBSS. The phenotype was found
to be mild at 125 M, and obvious at 250 M or 500 M. Non-specific
effects were not observed at any concentration. As there were no
phenotypic differences between hearts knocked down with 250 M or 500
M, 250 M was used for all further studies. The first and second eMYH
morpholinos gave the same phenotype with a similar penetrance, therefore
embryo numbers pertain to both experimental morpholino groups pooled.
Mismatch, SC and untreated control groups were pooled with a minimum
of three embryos per control type, per developmental stage. Age-matched
‘untreated’ control embryos were opened at the same stage as other
embryos but morpholino/pluronic gel was not applied. HH14/19 represents
knockdown at HH14, harvesting at HH19; similar abbreviations were used
for all knockdown and harvesting stages.
Embryo isolation
Embryos were harvested using a fluorescent SV11 stereomicroscope
(Zeiss, Germany) to determine morpholino uptake, stage embryos, count
somites and perform external phenotypic analysis (Bellairs and Osmond,
1998; Hamburger and Hamilton, 1951). Data showing the numbers of
chick embryos alive at harvesting (HH19; 81 hours) and those that were
‘morpholino positive’ were collected from 250 M experiments and
statistically analysed (see below); n356 untreated, 164 SC, 38 eMYH
mismatch and 360 eMYH knockdown embryos.
Bioinformatics
To determine possible homologous relationships between human and
chicken MYH clusters, genomic DNA encompassing the identified cluster
on chicken chromosome 18 (genome.cse.ucsc.edu, coordinates G. gallus
build 18 positions 1-1768914) and the six known human swissprot proteins
(P35580.3, P11055.3, P13535.3, Q9UKX2.1, P12882.3, Q9Y623.2,
Q9UKX3.1) were used to predict all myosin-like genes in this region using
exonerate (Slater and Birney, 2005). Mouse, human and chicken MYH
genes showed large regions of conservation and clustering, although
orthology could not be determined. Translations of predicted genes were
aligned to the human proteins using muscle (Edgar, 2004) to produce a
phylogenetic tree (Guindon and Gascuel, 2003). Analysis of known and
predicted MYH genes revealed a single human-chicken orthologue of
MYH13 and lineage-specific duplications of MYH genes in the chicken
genome. The addition of identified MYH genes from the anole lizard
(Anolis carolinensis) and zebrafinch (Taeniopygia guttata) confirmed that
these expansions are largely avian specific, suggesting that at the point of
divergence of the diapsids (birds, lizards) and synapsids (mammals) a small
MYH gene family existed. Following the divergence of lizard and birds the
independent expansion of avian and mammalian MYH genes began. In
these examples of out-paralogue expansions it is not advisable to
computationally infer specific function to single genes, hence RNA
expression studies were performed.
RNA expression
RNA was extracted from chick HH12, 14, 16, 19, 22, 24 and 26 hearts, and
human 7-week foetal heart and 8-week skeletal muscle using RNeasy
Micro and Midi Kits (Qiagen, UK). Commercial RNAs used were: human
foetal skeletal muscle (19 weeks; AMS Biotechnology, UK) and human
adult skeletal muscle, human adult heart and human foetal heart (12-31
weeks pooled samples; Clontech, USA). Reverse transcription reactions
were performed using random primers with SuperScript III Reverse
Transcriptase (Invitrogen, UK), and 1 g of RNA per reaction. PCR
reactions: 95°C for 4 minutes, then 35 cycles of 94°C for 30 seconds, 56°C
for 30 seconds, 72°C for 1 minute for all primers except actin and eMYH
which required annealing at 60°C. Primers were designed to chick eMYH,
5-GCCAAGGCAAATTTAGAGAAGA-3 and 5-TCATTAATG -
GTGCGCTGTTG-3 (95 bp RT-PCR product); human MYH1, 5-
CTGGCTCTCCTCTTTGTTGG-3 and 5-GAGAGCAGACACA GTCT -
GGAAA-3 (105 bp); human MYH2, 5-GGAGAGGGAGCTGGTGGA-
3 and 5-CTCTCTGAAAAGGGCAGACA-3 (84 bp); human MYH3, 5-
AAATGGAAGTGTTCGGCATA-3 and 5-GGCGTACACATCC -
TCTGGTT-3 (221 bp); human MYH4, 5-GGACCAGCTTAGTG -
AAATAAAAACA-3 and 5-TCGGGATAGCTGAGAAACCA-3 (151
bp); human MYH8, 5-TCTTCTGGAAGAAATGAGAGATGA-3 and 5-
GCTTCTCTCCTTTGCAACATC-3 (117 bp); human MYH13, 5-
CGAGGCTCAAAATCGTCCA-3 and 5-AGAGTGAGCATCC -
GGTCATC-3 (141 bp); human -actin, 5-CCTGGCACCCAGCACAAT-
3 and 5-GGCGATCCACACGGAGTACT-3 (60 bp) (kindly provided by
Dr Andy Bennett, University of Nottingham). All primers spanned an
intron. Products were resolved on 1.5% agarose gels against Hyperladder
IV (Bioline, UK). Amplicons were cloned and sequenced (Biopolymer
Synthesis and Analysis Unit, University of Nottingham).
For in situ hybridization, human and mouse embryos were fixed in 4%
paraformaldehyde (PFA) in phosphate-buffered saline (PBS) overnight at
4°C, followed by dehydration, paraffin wax embedding and cutting of 8-
m-thick sections. Proteins were removed using proteinase K (20 mg/ml)
in PBS. A 221 bp PCR product of human MYH3 (NM_002470.2, 94-315
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bp) was ligated into pGEM-T (Promega) and used on both human and
mouse tissue. Antisense and sense probes were prepared by linearising
plasmids with ApaI and SalI, respectively. Digoxigenin (DIG)-UTP was
incorporated into riboprobes during in vitro transcription using DIG RNA
Labelling Mix (Roche) according to manufacturer’s instructions. Antisense
and sense probes were generated using SP6 and T7 polymerase,
respectively. The remainder of the in situ hybridization procedure was as
previously described (Kelberman et al., 2008).
Western blotting
Three HH19 hearts per ‘sample’ were dissected, snap frozen in liquid
nitrogen and stored at –80°C. Samples were resolved by SDS-PAGE gels
as previously described (Rutland et al., 2009) with 1 hour at room
temperature (RT) incubation with EB165 [eMYH; 1:500; Developmental
Studies Hybridoma Bank (DSHB), USA] (Cerny and Bandman, 1987) or
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; loading control;
1:1000; Abcam, UK), followed by 1 hour at RT with a mouse monoclonal
secondary antibody (Dako, Denmark). Immunoblots containing untreated,
SC and knockdown heart samples were performed in triplicate using
different samples and blots each time.
Phenotypic and immunohistochemical studies
Untreated control embryos were isolated at HH12, 14, 16, 19, 22, 24 and
26, fixed in 4% PFA, washed in 1 PBS, dehydrated in an ethanol series
and wax embedded in a transverse orientation. Serial 8 m sections were
taken (DSC1 microtome, Leica, Germany), dewaxed, rehydrated and
stained with Mayers haemalum (Raymond Lamb, UK) or used for
immunohistochemistry (see below). Unless otherwise stated,
morphological analysis was performed double blind using an Axioskop 2
microscope (Zeiss, USA).
Immunohistochemistry
After tissue rehydration, antigen unmasking was performed (microwaving
for 10 minutes in 10 mM sodium citrate, pH 6.0). An avidin-biotin
phosphatase amplification kit (StreptABComplex Duet Kit; Dako, Denmark)
was used according to manufacturer’s instructions including a 1 hour EB165
antibody incubation (1:50 eMYH; DSHB, USA) (Cerny and Bandman,
1987) and counterstaining in Mayers haemalum (Raymond Lamb, UK).
Alternatively, sections were subjected to 5 minute treatments of 3%
acetic acid (pH 2.5) and 1% Alcian Blue/acetic acid, 10 minutes in 50%
periodic acid solution, followed by 15 minutes in Schiff’s reagent before
ethanol dehydration.
Systematic random sampling
Systematic random sampling (Mayhew, 1991) was used to assess tissue
proportions throughout HH14/19 hearts [control (untreated, mismatch and
SC) and eMYH; n9 per group]. A 96-point grid was placed over every
third section throughout the heart, tissue type on each point was identified
(6879 points counted) and average tissue proportions were calculated and
tested for statistical significance (see below). Identical procedures were
used for HH14/17 chicks (n14 control, n16 eMYH knockdown; 7961
points counted).
Proliferation and apoptosis
Embryo isolation and processing methods were employed at HH14/19 (as
above) and cells visualised using a proliferating cell nuclear antigen
(PCNA) staining kit using the manufacturer’s instructions to indicate cell
proliferation (Zymed Laboratories, USA). Alternatively, embryos were
placed into 30% sucrose for 30 minutes, orientated in OCT and frozen
using liquid nitrogen-cooled isopentane. Serial sections were cut (20 M),
mounted, fixed for 3 minutes in 4% PFA and an ‘in situ Cell Death
Detection Kit’ (Roche Diagnostics, Germany) used to indicate apoptotic
cells in accordance with manufacturer’s instructions. Systematic random
sampling (Mayhew, 1991) was utilised to count positive cells against total
cell count in the ventricle, atrium and septum (minimum of n3 per eMYH
knockdown and control hearts) to calculate proportions of
proliferating/apoptotic cells for statistical analysis (see below).
Immunofluorescence and electron microscopy
Hearts from PFA-fixed chick embryos were dissected and immersed in 1
mg/ml hyaluronidase (Sigma) in PBS for 1 hour at RT, with permeabilisation
in 0.2% Triton X-100/PBS (PBT) for 45 min and blocked with 5%
preimmune goat serum in 1% BSA/TBS for 30 min at RT with primary
antibody incubations overnight at 4°C. Hearts were washed six times for 20
minutes in 0.002% PBT, incubated with secondary antibody either overnight
at 4°C or for 6 hours at RT, washed six times for 20 minutes each wash in
PBT and mounted for confocal microscopy. For immunostaining with EB165
(eMYH; DSHB), hearts were dissected, fixed overnight in 90%
methanol/10% DMSO at –20°C, rehydrated in PBS and immersed in 1
mg/ml hyaluronidase for 1 hour at RT. Blocking steps and subsequent
antibody incubations were carried out as above and counterstained using an
antibody against sarcomeric alpha-actinin (Ehler et al., 1999).
Analysis was carried out using a Zeiss (Germany) 510 confocal
microscope equipped with 405 diode, argon and helium neon lasers using
a 63/NA1.4 oil immersion objective. Data were processed in Image J
(NIH, USA). Antibodies used were: mouse anti-sarcomeric alpha-actinin
(Sigma, UK), rabbit anti beta-catenin (Sigma, UK), rabbit anti EH-
myomesin (Agarkova et al., 2000), rabbit anti-MyBP-C (Ahuja et al.,
2004), Cy2- or Cy5-conjugated anti-rabbit immunoglobulins and Cy3- or
Cy5-conjugated anti-mouse immunoglobulins (Jackson Immunochemicals,
USA). DAPI was purchased from Sigma (UK). Combinations of Cy2 and
Cy5 were used for lissamine and Cy3 and Cy5 for fluorescein-tagged
morpholinos.
Hearts undergoing transmission electron microscopy (n5 eMYH
knockdown, 5 control) were fixed, sectioned (0.5 m) and visualised using
a FEI Tecnai 12 Biotwin TEM at 4000-43,000 magnification.
Electrical activity and calcium signalling
Knockdown embryos (HH14/19; -, - or eMYH morpholinos) were
utilised for intracellular recordings of the electrical responses of heart cells.
Glass micropipettes (Sutter Instruments, USA) were pulled with a P-97
Flaming/Brown micropipette puller (Sutter Instruments, USA),filled with
3M KCl and connected to a Bridge Amplifier BA-1S (npi-Tamm,
Germany); a resistance of 60-80 MW was used. Recordings were displayed
on an oscilloscope (Instek, USA), digitised in parallel, and stored and
processed via Digidata 1440A with Axotape 10 Software (Molecular
Devices, USA).
Action potentials were classified on the maximal rate of rise (dV/dtmax),
action potential duration (APD) (APD50 and APD90 measured at 50% or
90% repolarization, respectively), amplitude, prominence of phase 4
depolarization, maximal diastolic potential and resting membrane potential.
For evaluation of Ca2+ transients, single cell cultures were incubated 2-3
hours post-plating with 1 M Fluoro-5 FF-AM (Invitrogen, USA) or Rhod-
2 AM (Anaspec, USA) (green and red fluorescent Ca2+ sensitive dyes,
respectively) for 10-15 minutes. Changes in intracellular Ca2+ were
detected by monitoring fluorescent dye intensity changes. Cell culture
dishes were mounted in a temperate controller on an inverted microscope
IX71 (Olympus, UK) using the appropriate excitation and emission filter
set (Semrock, USA). Fluorescent signal was monitored using a
photomultiplier (PTI, USA) coupled with an A/D digitiser and displayed
as F/Fo. n16 per MYH tested. The cardiomyocytes with no spontaneous
contraction in vitro were positive for Calcein-AM staining (cell viability
test) and negative for propidium iodine staining (membrane integrity test).
Patch clamp recordings
Standard whole-cell patch clamp configuration, including solutions and
voltage protocols, was as previously described (Davies et al., 1996; Hamill
et al., 1981; Wang and Duff, 1997). An EPC 10 amplifier under the control
and measuring of Patch Master (Heka Instruments) was used. RSeries
resistance was 0.5-3.0 MΩ (mean 1.6±0.2 MΩ) and membrane capacitance
was 3.8-4.9 pF (mean 5.1±0.6 pF).
Statistics
Levene’s test for equality of variances followed by t-test for equality of
means or Analysis of Variance (ANOVA) with post-hoc testing for multiple
groups on SPSS V17 (SPSS, USA) were used; P<0.05 was considered to
be significant.
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RESULTS
eMYH is expressed during early cardiogenesis
RNA expression profiling showed that eMYH was present in
chick heart at all stages analysed (HH12-26) (Fig. 1A). At HH14,
immunohistochemical eMYH (EB165)-positive staining was
seen throughout the myocardial wall (Fig. 1Ba). Intense
expression was seen throughout the outflow tract (OFT),
myocardium of the atrial ventricular canal (AVC) and atrial
myocardial walls at HH19-26 (Fig. 1Bb,d). In addition, eMYH
staining was identified in the atrial septum, as it extended into
the atrial chamber and persisted once it had fused with
negatively stained endocardial cushions (Fig. 1B). Lower levels
of staining were present throughout the ventricular myocardial
walls and trabeculae (Fig. 1Bb,c). Expression of eMYH was also
observed within the sinus venosus of the heart and myotome-
derived premuscle masses (data not shown). As shown in Fig.
S1C,F in the supplementary material, eMYH expression was
localised to the heart tube and confocal microscopy analysis
revealed that eMYH was expressed by a subset of
cardiomyocytes and localised close to the plasma membrane
(small arrowheads in Fig. 1C). In a subset of cardiomyocyte
myofibrils that express eMYH, localisation to the A-bands was
seen (arrows in Fig. 1C), as judged by counterstaining for the Z-
disc protein sarcomeric alpha-actinin. To determine whether
eMYH expression can be correlated with cardiomyocyte
populations originating from the primary or secondary heart
field, eMYH was localised in early heart whole-mount
preparations. At all developmental stages analysed (7, 8 and 12
somites, equivalent to HH9 to early HH11), eMYH was
restricted to the heart itself, but was not expressed
homogeneously (see Fig. S1 in the supplementary material).
More eMYH-positive cells were detected caudally in the heart at
all stages, but the area of expression was too broad for a strict
correlation with secondary heart field populations.
Validation of controls and survival rates of
embryos
All of the control embryos analysed both internally and externally
(n83) had normal phenotypes, except for one untreated control
embryo in the HH16 control group (1/13), which had a
comparatively small heart and septum. As a small heart and septum
was not seen in any other control embryo it was presumed to be
due to developmental variation.
Data from untreated embryos (n356) collected at HH19 showed
a survival rate of 86.2%, SC embryos (n164) 83.5%, eMYH
mismatch knockdown (n38) 89.4% and those receiving eMYH
morpholino (n360) a rate of 83.3% (no significant differences,
P0.9). Those identified as ‘morpholino positive’ (determined by
the level of fluorescence), totalled 60.6% of SCs, 47.1% of eMYH
mismatch and 60% of eMYH knockdown embryos (no significant
differences, P0.7). Knockdown and survival rates for the MYH
knockdown hearts (n203) were as previously published (Rutland
et al., 2009). Survival rate for MYH knockdown embryos (n47)
was 81% and morpholino uptake 60%. We have previously
demonstrated that knockdown of chick MYH leads to abnormal
atrial septal development (Ching et al., 2005; Rutland et al., 2009),
whereas knockdown of MYH causes heart enlargement but atrial
septal development was normal (C.S.R., A.A., A.T. and S.L.,
unpublished data).
Knockdown of eMYH leads to dilated
cardiomyopathy
Analysis of eMYH protein level showed a significant reduction of
82.6% (P0.02) in knockdown hearts compared with control hearts
(Fig. 1D). Ventricular size was analysed externally when harvesting
and upon internal phenotypic analysis (Table 1). The samples
below pertain only to those that underwent both comparisons.
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Fig. 1. eMYH is expressed during chick cardiogenesis and is
knocked down upon morpholino application. (A)mRNA expression
was present in HH12, 14, 16, 19, 22, 24 and 26 embryonic heart tissue
(arrow). No signal was observed in negative (–ve) RT and –ve PCR controls.
(B)eMYH was found throughout the HH14 heart wall (a), outflow tract
(OFT), atrium (At), atrial septa (arrowhead) and, to a lesser extent, HH19
ventricular (V) myocardium and trabeculae (b). At HH26 (c,d), staining was
seen in the ventricle, left and right atria (LA and RA, respectively) and atrial
septa. Endocardial cushion (EC) staining was absent. Scale bars: 200m in
a; 500m in b-d. L, liver. (C)Confocal micrographs show eMYH staining
(a,b), particularly associated with plasma membranes (small arrowheads),
A-bands of emerging myofibrils (arrows) but not in all myofibrils (large
arrowheads) compared with sarcomeric alpha actinin (a,c). Scale bar:
10m. DAPI labels nuclei blue. (D)Western analysis demonstrated an
optical density of 0.27 (eMYH knockdown) and 1.57 (control). *P<0.02.
Error bars represent s.e.m.
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Following HH12/19 knockdown, it was noted that 7 of 10 embryos
had enlarged ventricular chambers (70%) compared with controls
(0/12; Fig. 2B compared with 2A). This external phenotype was
also present following knockdown at HH14/19 (38/43 or 88%; Fig.
2D compared with 2C) and HH16/19 (5/8 or 62.5%) and was
confirmed upon internal phenotypic analysis. Stereology showed
knockdown hearts were 26% larger than controls (P0.05). None
of the control embryos had an enlarged ventricular chamber (0/83;
Fig. 2A,C).
Trabeculae can be observed from about HH17, with distinct
structures by HH19 (Ben-Shachar et al., 1985; Sedmera et al.,
1997). In HH14/17 hearts, trabeculae could not be distinguished
and no stereological differences in ventricular size were observed
(P>0.05; n14 control, n16 eMYH knockdowns). By contrast,
internal phenotypic analysis of HH19 knockdowns showed
ventricular dilation, thinner ventricular walls and reduced
trabeculation [Fig. 3A,B,E,F (controls) compared with 3C,D,G,H
(eMYH knockdown hearts)]. Trabeculae appeared to be reduced in
both size and number in the knockdowns harvested at HH19
(n61), with all of the HH12/19 and HH16/19 (10 and 8,
respectively), and 42 of 43 HH14/19 embryos affected, whereas
none of the control embryos (n83) had reduced trabeculation
(Table 1). Stereological analysis showed that in controls the
average percentage of the heart composed of ventricular wall and
trabeculae was 20.38±1.10%, whereas in eMYH knockdown hearts
this was reduced to 12.09±0.94%, a decrease of 40.66%
(P0.0001; n9 for control or eMYH knockdown; numbers
indicate average±s.e.m.).
Knockdown of eMYH leads to abnormal atrial
septal development
Atrial septal development was analysed in embryos with eMYH
knocked down at HH12 (prior to septa initiation), HH14 (around
the stage of septa initiation) and HH16 (as the septum is growing)
and harvested at HH19. The septa were noted to be abnormal in 60
out of 61 embryos in comparison with the control group, in which
all except one heart showed normal septal development (n83)
(Table 2). The most severely affected hearts formed a small
knuckle-shaped outgrowth from the dorsocranial atrial wall (Fig.
3C,G,J) and the less severely affected formed a normal-shaped
septum that was reduced in size (Fig. 3D,H,K) in comparison with
controls (Fig. 3A,B,E,F,I). At HH12/19, the septa were found to be
knuckle-shaped in 8/10 of the knockdown embryos (80%; Fig. 3C)
and the remaining embryos had a small septum (2/10; Fig. 3D,K).
In HH14/19 hearts, a knuckle-shaped outgrowth was seen in 8 out
of 43 (19%) and a small septum in 34 out of 43 embryos (79%;
Fig. 3E-J). In one knockdown embryo, the septum appeared normal
in size, although this embryo did have an enlarged heart. In
HH16/19 embryos, 3 out of 8 (38%) had a knuckle-shaped septum
and 5 out of 8 (62%) embryos had a small septum. HH14/17
control chicks, all presented with an atrial septum that showed
natural variation in size as shown in Fig. 3L,M (n14), whereas a
septum was not observed in any of the eMYH knockdown hearts
(n16, Fig. 3N).
Stereological data (HH14/19) showed that control septa
represented 1.19±0.43% (average±s.e.m.; n9) of the heart,
whereas in eMYH knockdown hearts the septa were just
0.29±0.11% of the heart (n9; all classed as having a small septa),
a decrease of 75.26% (P0.04). Stereology showed no significant
differences in endocardial cushions, atrial tissue, or wall or lumen
sizes of the OFT and AVC. The HH14/17 stereology showed no
significant differences within any of the tissue types counted
(P>0.05; n14 control, n16 eMYH knockdown; stereological
septal analysis was not possible owing to the small septum size at
this stage).
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Table 1. Summary of embryos with abnormal phenotype to the ventricular chamber
Ventricle of heart* Trabeculation*
Stage† Embryo type‡ Total Enlarged Normal Reduced Normal
HH12/19 Control 12 0 12 0 12
eMYH knockdown 10 7 3 10 0
HH14/19 Control 58 0 58 0 58
eMYH knockdown 43 38 5 42 1
HH16/19 Control 13§ 0 13 0 13
eMYH knockdown 8 5 3 8 0
*Assessment of ventricular size and degree of trabeculation based on qualitative analysis of either gross morphological features (ventricle) or histological serial sections
(trabeculae).
†Stage of development when knockdown/harvesting were performed.
‡Control embryos include standard control, mismatch and untreated; eMYH denotes embryonic myosin heavy chain.
§One out of a total of 13 embryos had a small heart and a reduced septum.
Fig. 2. eMYH knockdown leads to an enlarged heart in the chick.
(A-D)Morpholino applied at HH12 (B) or HH14 (D), with harvesting at
HH19 for eMYH knockdowns (B,D) and controls (A,C). External
phenotypic analysis showed that eMYH knockdown embryos at HH12
(B) and HH14 (D) had an enlarged heart (arrowhead), in comparison
with controls (A,C). Scale bar: 500m for all panels. H, head. Asterisk
indicates outflow tract. Incubation periods: HH12, 50 hours; HH14, 54
hours; HH16, 57 hours; HH19, 81 hours. D
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Electrical activity and calcium signalling are
aberrant upon eMYH knockdown
Intracellular recordings of individual cardiomyocytes from
spontaneously beating hearts (Arguello et al., 1986; Polo-Parada et
al., 2009) in the presence of a morpholino (e-, - or MYH) at
HH19 showed regional differences in the action potential (AP)
phenotype in comparison with control hearts. Hearts treated with
eMYH morpholino exhibited abnormal beating patterns
characterised by absent or weak contractions, with a complete
absence of AP in 75-80% of ventricular cells. However, electrically
silent cells exhibited a large range of depolarised resting membrane
potentials (Fig. 4E). Within the ventricular cells that did exhibit
spontaneous APs, small amplitudes, long duration and slow rate of
rise were observed compared with controls (Fig. 4B). By contrast,
the atria displayed normal contractions and spontaneous APs,
which were characterised by a decrease in amplitude and maximal
rate of rise and an increase in duration (Fig. 4A). The long duration
AP could be attributed at least in part to a decrease in IK+
(intracellular potassium) (Fig. 4F). Hearts treated with either - or
MYH morpholino did not present any apparent differences in
contraction or AP characteristics in either the atria or ventricles in
comparison with controls (n6 for - or MYH morpholino
treated; Fig. 4A,B).
Ca2+ transients (increases in cytosolic Ca2+) have previously
been described in conjunction with AP in cardiomyocytes.
Therefore, cytosolic Ca2+ was explored during the manipulation of
e-, - or MYH in single isolated cells. Upon knockdown of
eMYH, atrial cells displayed large variability in the duration of the
Ca2+ transient, showing with some regularity a superimposition of
a second or third maximal Ca2+ peak, and some small or aborted
Ca2+ transient peaks (Fig. 4C). MYH morpholino induced a
modest change in Ca2+ transients, characterised in general by a low
rise and decay with some small or aborted transients (Fig. 4C).
MYH morpholino-treated atrial cells showed irregular Ca2+
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Fig. 3. Abnormal atrial and ventricular development upon eMYH knockdown. (A-K)Morpholino was applied at HH12 (B-D) or HH14 (F-H),
with harvesting at HH19 for eMYH knockdowns (C,D,G,H) and controls (A,B,E,F). Knockdowns at HH12/19 (C,D) and 14/19 (G,H) had thinner
ventricular walls and reduced trabeculae in comparison with controls (A,B,E,F). Abnormal atrial septa were seen in the knockdowns, with either a
knuckle-shaped outgrowth (arrowheads in C,G,J) or normally shaped but reduced septa (arrowheads in D,H,K) compared with controls (arrowheads
in A,B,E,F,I). From gross morphological phenotypic studies, hearts shown in A-F and H were normal in size whereas that shown in G was enlarged. I,
J and K are enlarged views of the boxed areas in D, F and G, respectively. (L-N)Morpholino was applied at HH14 and tissue was harvested at HH17.
HH14/17 controls (L,M) had stage-appropriate septa (arrowheads) and eMYH knockdowns (N) had no discernable septum. Scale bars: 500m for
A-H; 200m for I-K; 100m for L-M; At, atrium; OFT, outflow tract; SC, standard control; V, ventricle. Asterisks indicate trabeculae. Incubation
periods: HH12, 50 hours; HH14, 54 hours; HH16, 57 hours; HH17, 62 hours; HH19, 81 hours.
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transient frequency, characterised mainly by superimposition of
several spikes in a short period of time, inducing a large increase
in Ca2+ levels (Fig. 4C). eMYH knockdown induced small changes
in Ca2+ transient frequency in ventricular cells, characterised
mainly by a moderate extension of the plateau phase in some of the
Ca2+ transients observed (Fig. 4D). MYH morpholino did not
induce any appreciable change in Ca2+ transients in ventricular
cells, whereas MYH knockdown induced a decrease in the rise
time during the Ca2+ transient and exhibited some small or aborted
Ca2+ transients (Fig. 4D).
Sarcomeres are normal in eMYH knockdown
hearts but tissue integrity is poor
Immunostaining and confocal microscopy of whole-mount heart
preparations were performed to investigate eMYH knockdown
effects at a subcellular level. Interestingly, the myofibrils (visualised
with antibodies against sarcomeric -actinin as a Z-disc protein)
were relatively normal and no immature structures, such as
premyofibrils, were observed (Rhee et al., 1994). The number of
myofibrils per individual cell appeared comparable to controls. A
subset of the cardiomyocytes showed completely diffuse staining for
alpha-actinin (asterisk in Fig. 5); however, DAPI revealed that these
were dividing cardiomyocytes in the process of disassembling their
myofibrils (Ahuja et al., 2004). The cell-cell contact protein -
catenin also showed normal localisation around the plasma
membrane of the cardiomyocytes (Hirschy et al., 2006) coupled with
some nuclear signal. However, areas of poor tissue integrity were
focally detected in all eMYH morpholino-treated hearts (arrows in
Fig. 5C, compare with unaffected area in Fig. 5B; 4/12 eMYH
morpholino-treated hearts were classified as moderately affected,
8/12 were severely affected), but were never observed in control
hearts. To investigate whether other parts of the sarcomere were
altered by eMYH knockdown, whole-mount preparations were also
stained with antibodies against MyBP-C and EH-myomesin as
markers for the A-band and M-band, respectively. Whereas the
striations appeared indistinguishable from control cardiomyocytes,
the disrupted tissue phenotype could again be observed (see Fig. S2A
in the supplementary material). Electron microscopy also revealed
poor tissue integrity but generally desmosomes, mitochondria and
muscle fibres were comparable to controls in cells not undergoing
apoptosis (see Fig. S2B in the supplementary material).
Reduced levels of eMYH did not affect cardiac
proliferation
A total of 21,841 cells were identified as either PCNA positive
(proliferating) or negative. In atria from control hearts, 57±10%
(average percentage±s.e.m.) were PCNA positive, and in eMYH
knockdown atria 54±6% cells were stained. In the septa, 45±3%
positive cells were present in controls in comparison with 44±6%
in eMYH knockdown tissue. The ventricles contained 64±17%
PCNA-stained cells in controls in comparison with 70±2% in
eMYH knockdowns. There were no significant differences between
proliferation levels in either group in any of the regions analysed
(P0.8 for the atria and septa and P0.7 for the ventricles).
Increased levels of apoptosis were observed
following eMYH knockdown
A total of 9499 cells were identified as either apoptosis ‘positive’
or ‘negative’ in HH14/19 hearts (n3 per group, average
percentage±s.e.m.; see Fig. S3 in the supplementary material).
Control atria showed 1.22±0.36% positive cells compared with
6.17±1.29% in knockdowns. In the septa, 0.87±0.44% positive
cells were present in controls compared with 15.73±2.01% in
eMYH knockdown samples. The ventricles contained 1.07±0.50%
apoptotic cells in control hearts in comparison with 3.42±0.60% in
eMYH knockdowns. The statistics indicate significant increases in
apoptosis in eMYH knockdown hearts in comparison with controls
in all regions analysed (P0.002 septa, P0.02 atria and P0.04
ventricles, increases of 18%, 5% and 3%, respectively). The eMYH
total cell numbers were decreased by 60% in the septa, 52% in the
atria and 35% in the ventricles of eMYH knockdown chicks in
comparison with controls.
Expression studies suggest human MYH3 is the
functional homologue of chick eMYH
RT-PCR was performed to compare the expression levels of the six
human skeletal MYH genes present as a cluster on chromosome 17
(MYH1, MYH2, MYH3, MYH4, MYH8 and MYH13). MYH3 was
the only gene expressed in the human foetal and adult heart (see
Fig. S4 in the supplementary material). In situ hybridisation
confirmed that MYH3 was localised to atrial and ventricular
myocardial walls, and skeletal muscle around ribs and bronchioles
in 4, 5.5 and 7 week human embryos (Fig. 6A-F), with similar
expression in E11.5 mouse embryo (Fig. 6G,H).
DISCUSSION
Embryonic MYH has a role in skeletal muscle development
(Lagrutta et al., 1989; Lyons et al., 1990; Tajsharghi et al., 2008).
Data presented here demonstrates that eMYH is also expressed
during early cardiogenesis and plays a role in heart development.
The expression patterns of both - and MYH have been
described previously in the developing chick. MYH is
predominately expressed in the atrium and atrial septum and is
expressed at lower levels in the developing ventricular chambers
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Table 2. Summary of embryos with abnormal atrial septa formation
Atrial septation*
Stage† Embryo type‡ Total Knuckle Small Normal
HH12/19 Control 12 0 0 12
eMYH knockdown 10 8 2 0
HH14/19 Control 58 0 0 58
eMYH knockdown 43 8 34 1
HH16/19 Control 13§ 0 1 12
eMYH knockdown 8 3 5 0
*Qualitative assessment of atrial size obtained from serial histological sections.
†Stage of development when knockdown/harvesting were performed.
‡Control embryos include standard control, mismatch and untreated; eMYH denotes embryonic myosin heavy chain.
§One out of a total of 13 control embryos had a small heart and a reduced septum.
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(Rutland et al., 2009; Somi et al., 2006). Though initially expressed
throughout the heart tube, MYH becomes predominate in the
ventricular myocardium as development proceeds (Somi et al.,
2006). By comparison, expression of eMYH was demonstrated in
the early looping heart, and subsequently throughout the
myocardium of the OFT, atrium and atrial septum, and at lower
levels to the ventricular chamber. Knockdown of eMYH in the
chick resulted in abnormal atrial septal development, similar to that
seen upon MYH knockdown (Ching et al., 2005; Rutland et al.,
2009). The atrial septum either failed to form with only a small
outgrowth of the dorsocranial wall observed or a small septum
formed in comparison with controls. Knockdown at different stages
of septal development (HH12-HH16) showed no temporal effect
with the phenotypes present at high penetrance (98% of eMYH
knockdown embryos affected). In addition, there was an absent
atrial septum in the HH14/17 knockdown hearts (only about 8
hours between knockdown and harvesting). Together, these data
suggest that eMYH plays a specific and crucial role in atrial septa
initiation and maintenance. Although the role eMYH plays in atrial
septal formation is not fully understood, the 18% increase in
apoptosis in the eMYH knockdown hearts suggests that eMYH
might aid cell survival. Knockdown of eMYH also resulted in an
enlarged heart and reduced trabeculation; however, no effect was
observed upon myofibril assembly or maintenance. The enlarged
external ventricular phenotype was observed in 82% and reduced
trabeculae in 98% of eMYH knockdown hearts, with stereology
indicating that the ventricular wall and trabeculae together were
just 69% of the expected value. As the ventricle was enlarged but
the wall was thinner, it was deemed appropriate to define the HH19
enlarged heart as dilated cardiomyopathy (Maron et al., 2006). This
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Fig. 4. Changes in cardiac action potential, intracellular Ca2+ and IK+ in vivo and in vitro in e-, - and MYH knockdowns.
(A,B)Characteristics of action potentials from single cardiomyocytes from the atrium (A) or ventricle (B) of spontaneous beating hearts of controls
(n58 atria, 69 ventricles) or eMYH (n24 atria, 22 ventricles), MYH (n31 atria, 28 ventricles) or MYH (n32 atria, 36 ventricles) knockdowns.
(C,D)Changes in intracellular Ca2+ levels in spontaneous single isolated knockdown cells from the atrium (C) and ventricle (D). (E)Resting
membrane potential (RMP) from atrial and ventricular cells of control (n32 atria, 47 ventricles), eMYH beating (n24 atria, 26 ventricles) and non-
beating (n43 atria, 38 ventricles) cells and MYH- (n22 atria, 26 ventricles) and MYH- (n16 atria, 25 ventricles) treated cells. (F)Rapidly
inactivating K+ current normalised to the mean of the IK+ control from atrial and ventricular cells, respectively (n36 atria, 45 ventricles), and eMYH-
(only spontaneous beating cells; n52 atria, 65 ventricles), MYH- (n32 atria, 34 ventricles) and MYH- (n17 atria, 22 ventricles) treated cells.
Error bars represent mean±s.e.m. *P<0.01.
D
E
V
E
LO
P
M
E
N
T
phenotype is also consistent with the increased tissue disintegration
seen in subcellular analysis of embryonic heart structure and by an
increase in apoptosis in eMYH knockdowns compared with
controls. Apoptosis has previously been associated with dilated
cardiomyopathy in humans and animal models during development
and in the adult (Das et al., 2010; Guerra et al., 1999; Tintu et al.,
2009; Wencker et al., 2003) and is potentially a mechanism in this
disease (Wencker et al., 2003). Therefore, it was not unexpected
that apoptosis was observed in these eMYH knockdown enlarged
hearts. Data presented in Fig. 5 suggests that eMYH knockdown
does not affect myofibrillogenesis or myofibril maintenance per se
but results in focal impaired tissue integrity in the heart. These data
might be explained by the expression of eMYH in a subset of the
cardiomyocytes and its expression at the plasma membrane,
suggesting a stabilising role in the cytoskeleton (Fig. 1C).
Many different mutations in MYH7 (human analogue of MYH)
are known to cause cardiomyopathy (Walsh et al., 2010), with
different mutations also associated with skeletal muscle myopathies
(Meredith et al., 2004; Tajsharghi et al., 2003). In addition, some
families with mutations in MYH7 have both cardiomyopathy and
myopathy (Tajsharghi et al., 2007), and mutations have been
associated with cardiomyopathy in infants and children (Towbin et
al., 2006). Both MYH7 and MYH6 (human homologue of MYH)
are known to be involved in normal atrial septal development, with
families with mutations in these genes afflicted with ASDs (Budde
et al., 2007; Ching et al., 2005). Furthermore, mutations in MYH6
have also been found in individuals with cardiomyopathy (Carniel
et al., 2005). Interestingly, mutations in the structural protein
cardiac -actin have been associated with atrial septal defects
(Matsson et al., 2008) or cardiomyopathy (Mogensen et al., 1999;
Olson et al., 2000; Olson et al., 1998), with some individuals with
mutations having both defects (Monserrat et al., 2007). To our
knowledge, MYH3 or eMYH have not previously been associated
with heart abnormalities in humans or animal models. The data
presented here demonstrates that MYH3 is the only skeletal MYH
gene family member expressed in the human foetal heart,
expressed in both the atrial and ventricular regions. Mutations in
MYH3 have been associated with distal arthrogryposis type I, 2A
(Freeman-Sheldon syndrome) and 2B (Sheldon-Hall syndrome)
(Alvarado et al., 2011; Toydemir et al., 2006). Mutations are largely
missense, and are primarily to the head domain, potentially
affecting the catalytic activity of MYH3. However, in many cases
the consequence of a gene mutation is poorly understood.
Therefore, different types of mutations might lead to different
defects, such as ASDs with certain mutations and cardiomyopathy
or skeletal myopathies with other mutations. Knockdown of chick
eMYH leads to haploinsufficiency and, hence, a loss of function.
The excitation-contraction coupling process is fundamental to
heart physiology: the electrical stimulus is usually an AP and the
mechanical response is a contraction. The vast majority of papers
on cardiac excitation-contraction coupling deal only with the
ventricle (Fabiato and Fabiato, 1979; Langer, 1973; Orchard and
Brette, 2008). In this study, we have shown the differing effects
following the manipulation of e-, - or MYH in both the atria and
ventricle at early stages of heart development, which might result
in alterations between the generation of the electrical activity of the
cells and their Ca2+ transients. These Ca2+ transient changes are
fundamental to proper activation of the machinery of contraction,
in which MYH plays a key role (Chandra et al., 2007; Dillmann,
2009; Khait and Birla, 2009), but also to the regulation of gene
expression (Webb and Miller, 2003). Evidence is presented
suggesting that eMYH has a major impact on the AP properties of
the atrial and ventricular cells, with AP characteristics that are
normally found during very early heart development (Arguello et
al., 1986). These data suggest that eMYH might play a key role in
the normal development of the AP in these regions. Some of the
AP changes in eMYH-treated cells (such as the prolongation of the
AP duration) resemble phenotypes described in NKX2.5- (Briggs
et al., 2008; Pashmforoush et al., 2004) and TBX5- (Bruneau et al.,
2001) deficient mice (which also exhibit atrial septal and
conduction defects) or humans with heart failure (Kaab et al.,
1998). Thus, it could be possible that eMYH knockdown alters
these and/or other common proteins/pathways (such as the
reducing potassium channel proteins Kv1.2, Kv1.5 and Kv2.1)
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Fig. 5. The sarcomeres appear to form
normally upon eMYH knockdown
although the heart tissue has myocyte
loss. (A-C)Confocal micrographs of HH19
whole-mount control (A) and eMYH-
treated (B,C) hearts show -catenin-
labelled cell borders (second column, red
signal in overlay) and sarcomeric alpha-
actinin-labelled Z-discs (third column,
green in overlay) and DAPI-stained nuclei
(fourth column, blue signal in overlay). B
shows an unaffected area and C shows
tissue disintegration (arrows). Asterisk
denotes dividing cell with disassembled
myofibrils. Scale bar: 10m.
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resulting in similar phenotypes. Alternatively, changes in the
mechanical forces in these altered hearts might result in a different
microenvironment for the cardiomyocytes inducing a re-
differentiation or de-differentiation process in these cells (Porter
and Turner, 2009; Schenke-Layland et al., 2008). Furthermore,
neither MYH nor MYH knockdown had a major impact in the
AP morphology from the atria or ventricles. We found that a
decrease in eMYH expression induces a disruption not only in the
contraction of these cells but also in their ability to generate an AP,
decreased IK+ and Ca2+ transient spikes (in ~80% of the ventricular
myocytes). One possible explanation is that these electrically
inactive cells represent ventricular cells that will undergo apoptosis,
which is supported by the increase in apoptotic cells in the eMYH
knockdown ventricles in comparison with controls. If this is the
case, it raises new questions: Why are ventricular cells more
sensitive than atrial cells? Is this a sign that early in development
the excitation-contraction mechanism is tightly interrelated? If so,
at what point in development does this interrelation become looser?
Our current understanding of these issues is limited and further
insights are required. Changes in the flow or load to the embryonic
heart results in alterations in the composition and function of the
cardiac microenvironment, modifying size, structure and function
(Porter and Turner, 2009). Thus, the effects observed by eMYH
reduction could be attributed to some of these factors.
It is recognised that intracellular Ca2+ plays a key role in the
proper contraction of cardiomyocytes (Rigoard et al., 2009). In this
study, we show that manipulation of e-, - and MYH have an
impact on the profile of the spontaneous Ca2+ transients in atrial and
ventricular cells. To what extent these changes in intracellular Ca2+
might affect the ability of cardiomyocytes to generate the proper
force remains to be analysed. It is also well established that
intracellular Ca2+ plays an important role not only in the contraction
process but also in the modulation of many Ca2+ dependent
intracellular functions. It remains to be elucidated whether the
changes induced by manipulation of different MYHs are sufficient
to temporarily or permanently alter any of these processes.
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Fig. 6. In situ hybridisation of human MYH3 on human and mouse foetal tissues. (A-H)MYH3 in situ hybridisation on human 4 (A), 5.5
(B,C) and 7 (D-F) week foetal and E11.5 mouse (G,H) sections, with antisense (A-E,G) and sense negative control (F,H) probes. MYH3 is present in
the ventricle (Vent) and sinus venosus (SV) at 4 weeks (A). At 5.5 weeks, MYH3 is observed in the ventricle, primary bronchus skeletal muscle (PB)
(B,C) and in the atrium, ventricle and skeletal muscle around ribs and bronchi (B) at 7 weeks (D,E). C and E show enlarged views of the boxed areas
in B and D, respectively. (G)In the E11.5 mouse embryo, MYH3 is visualised in the atrium (A) and ventricle. Scale bars: 5m for A,B,D,F-H ; 2.5m
for C,E.
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The data presented here demonstrates that eMYH is present in
the early developing heart, and that it plays crucial roles during
cardiogenesis, specifically in atrial septation and in normal heart
function. Novel insights into the role that the MYH family plays in
the electrical activity and calcium signalling within the developing
heart are presented. These data suggest that the human functional
homologue to eMYH, which we postulate to be MYH3, could
provide novel insights into the molecular genetics of cardiovascular
disorders and, hence, would be a candidate gene worthy of further
investigation.
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